

CITATION REPORT

List of articles citing

Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments

DOI: 10.1111/apt.12569

Alimentary Pharmacology and Therapeutics, 2014, 39, 254-69

Source: <https://exaly.com/paper-pdf/59596700/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
289	Clinical Correlation between Serum Cytokeratin-18 and Metabolic Parameters in Patients with Sonographic Non-alcoholic Fatty Liver Disease. 2014 , 64, 206		
288	Biomarkers in nonalcoholic fatty liver disease. 2014 , 28, 607-18		91
287	Non-alcoholic fatty liver disease: what the clinician needs to know. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12956-80	5.6	117
286	Personalizing care for nonalcoholic fatty liver disease patients: what are the research priorities?. 2014 , 11, 735-743		5
285	A comparison of FibroMeter [®] NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. 2014 , 49, 1343-8		29
284	Debate--A bridge too far: Nonalcoholic fatty liver disease will not exhaust the donor pool. 2014 , 20 Suppl 2, S38-41		4
283	Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. 2014 , 28, 637-53		218
282	Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 2121-30.e1-2	6.9	83
281	Editorial: novel association between serum Pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 773-4	6.1	0
280	Nonalcoholic fatty liver disease. 2015 , 1, 15080		366
279	Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 731-40	6.1	46
278	Practical approach to non-alcoholic fatty liver disease in patients with diabetes. 2015 , 32, 1121-33		10
277	Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 106-16	6.1	13
276	Intravoxel Incoherent Motion Diffusion Weighted MR Imaging at 3.0 T: Assessment of Steatohepatitis and Fibrosis Compared with Liver Biopsy in Type 2 Diabetic Patients. <i>PLoS ONE</i> , 2015 , 10, e0125653	3.7	27
275	Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. <i>PLoS ONE</i> , 2015 , 10, e0128774	3.7	46
274	Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan [®])). <i>World Journal of Gastroenterology</i> , 2015 , 21, 11914-23	5.6	15
273	Cost-utility analysis of nonalcoholic steatohepatitis screening. 2015 , 25, 3282-94		35

272	A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease. 2015 , 94, e758		60
271	Magnetic resonance elastography (MRE) in assessing hepatic fibrosis: performance in a cohort of patients with histological data. 2015 , 40, 760-5		26
270	Incorporation of Noninvasive Measures of Liver Fibrosis Into Clinical Practice: Diagnosis and Prognosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 2190-204	6.9	37
269	Management and diagnosis of fatty liver disease. 2015 , 9, 671-83		7
268	Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. 2015 , 15, 607		74
267	Screening of nonalcoholic fatty liver disease in patients with coronary heart disease by transient elastography: proceed with caution. 2015 , 127, 75-6		
266	WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. 2015 , 41, 1161-79		390
265	Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins. 2015 , 149-173		1
264	Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. 2015 , 9, 481-3		2
263	Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. 2015 , 75, 1373-92		50
262	Nonalcoholic fatty liver disease - current status and future directions. 2015 , 16, 541-57		61
261	Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. 2015 , 110, 1298-304		53
260	[Ultrasound elastography]. 2015 , 55, 949-55		1
259	Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. 2015 , 62, 182-9		104
258	Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 327-335	6.9	42
257	Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients. 2016 , 16, e40263		13
256	Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. <i>World Journal of Gastroenterology</i> , 2016 , 22, 7236-51	5.6	127
255	A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease. 2016 , 2016, 6491420		8

254	Increasing aortic stiffness is predictive of advanced liver fibrosis in patients with type 2 diabetes: the Rio-T2DM cohort study. 2016 , 36, 977-85		16
253	Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 2016 , 64, 2234-2243		39
252	Nonalcoholic fatty liver disease and elastography: Incremental advances but work still to be done. 2016 , 63, 1762-4		10
251	Early diagnosis of NAFLD-NASH transition using mid infrared spectroscopy. 2016 , 2016, 3602-3605		2
250	How to best diagnose NAFLD/NASH?. 2016 , 111-123		
249	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. 2016 , 48, 55-61		16
248	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. 2016 , 59, 1121-40		275
247	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. 2016 , 64, 1388-402		2065
246	EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. <i>Obesity Facts</i> , 2016 , 9, 65-90	5.1	197
245	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. 2016 , 1, 156-164		73
244	Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 83-95	6.1	125
243	In search of new biomarkers for nonalcoholic fatty liver disease. 2016 , 8, 19-23		4
242	Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 366-79	6.1	22
241	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016 , 6, 31421	4.9	22
240	The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. 2016 , 36, 1549-57		67
239	Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. 2016 , 36, 1213-20		25
238	The intersection of nonalcoholic fatty liver disease and obesity. 2016 , 8, 323rv1		43
237	Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. 2016 , 150, 1811-1822.e4		69

236	The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease. 2016 , 111, 677-84		82
235	Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. 2016 , 20, 277-92		24
234	Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. 2016 , 65, 1161-71		43
233	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. 2016 , 150, 626-637.e7		438
232	Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. 2016 , 26, 1431-40		147
231	Noninvasive Differentiation between Hepatic Steatosis and Steatohepatitis with MR Imaging Enhanced with USPIOs in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study. 2016 , 278, 782-91		38
230	Distinguishing between Hepatic Inflammation and Fibrosis with MR Elastography. 2017 , 284, 694-705		72
229	Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). 2017 , 10, 379-390		23
228	Application of Ultrasound Elastography for Chronic Allograft Dysfunction in Kidney Transplantation. 2017 , 36, 1759-1769		17
227	Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 175-182	6.1	40
226	Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. 2017 , 41, 1207-1213		28
225	Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 447-456	6.1	73
224	Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis. 2017 , 101, 1867-1874		74
223	Liver and Spleen. 2017 , 13-45		
222	Collaboration, Not Competition: The Role of Magnetic Resonance, Transient Elastography, and Liver Biopsy in the Diagnosis of Nonalcoholic Fatty Liver Disease. 2017 , 152, 479-481		10
221	IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD - a pilot study. 2017 , 52, 1427-1434		18
220	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 617-627	6.1	94
219	Non-alcoholic fatty liver disease: A poorly known pandemic. 2017 , 149, 542-548		17

218	Non-alcoholic fatty liver disease: A poorly known pandemic. 2017 , 149, 542-548		0
217	Wet Biomarker-Based Assessment of Steatosis, Inflammation, and Fibrosis in NAFLD. 2017 , 16, 308-316		
216	MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. 2017 , 177, R145-R158		21
215	Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic?. 2017 , 37, 328-336		9
214	Ex vivo study of acoustic radiation force impulse imaging elastography for evaluation of rat liver with steatosis. 2017 , 74, 161-166		7
213	Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. 2017 , 37, 1065-1073		103
212	Liver stiffness measurement to platelet ratio index predicts the stage of liver fibrosis in non-alcoholic fatty liver disease. 2017 , 47, 721-730		11
211	Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. 2017 , 66, 123-131		202
210	Transient elastography as a noninvasive assessment tool for hepatopathies of different etiology in pediatric type 1 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 186-194	3.2	11
209	Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 345-353	6.1	39
208	Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency. 2017 , 37, 611-619		34
207	Serum microRNA-34a is potential biomarker for inflammation in nonalcoholic fatty liver disease. 2017 , 10, 163-171		5
206	Hígado graso no alcohólico en consulta de gastroenterología. 2017 , 26, 225-230		1
205	Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD. 2017 , 16, 298-307		6
204	Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. 2017 , 2017, 9729107		52
203	Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2017 , 12, e0188321	3.7	37
202	Non-alcoholic Fatty Liver Disease: A Clinical Update. <i>Journal of Clinical and Translational Hepatology</i> , 2017 , 5, 384-393	5.2	69
201	Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. 2018 , 286, 738-763		145

200	Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. 2018 , 42, 1900-1911		17
199	Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 546-551	2.2	28
198	Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1387-1396	6.1	31
197	<i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. 2018 , 33, 1795-1803		27
196	Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis. 2018 , 28, 3050-3058		26
195	Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 816-825	6.1	31
194	Valoraci3n de la enfermedad por h3gado graso no alcoh3lico desde el laboratorio cl3nico. 2018 , 11, 163-173		
193	New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease. 2018 , 23, 328-334		11
192	Blood-based novel biomarkers for nonalcoholic steatohepatitis. 2018 , 12, 501-515		1
191	Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. 2018 , 9, 115-121		16
190	A novel index including SNPs for the screening of nonalcoholic fatty liver disease among elder Chinese: A population-based study. 2018 , 97, e0272		10
189	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. 2018 , 33, 70-85		211
188	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. 2018 , 67, 2001-2012		79
187	Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. 2018 , 38, 715-723		15
186	Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 837-861	6.9	26
185	Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. 2018 , 38, 695-705		44
184	Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. 2018 , 53, 181-196		46
183	Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins. 2018 , 66, 661-668		3

182	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. 2018 , 12, 351-367		34
181	Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. 2018 , 68, 305-315		241
180	Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 504-515	6.1	27
179	Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese. <i>Obesity Reviews</i> , 2018 , 19, 281-294	10.6	15
178	Diffuse Liver Diseases: Role of imaging. 2018 , 39, 193-205		5
177	Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease. 2018 , 45, 243-249		24
176	Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C. 2018 , 5, ofy268		13
175	Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1109-1116	6.1	53
174	Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease. 2018 , 2018, 9252536		8
173	Obesity and Nonalcoholic Fatty Liver Disease: Role of Oxidative Stress. 2018 , 111-133		4
172	Non-alcoholic fatty liver disease--a chronic disease of the 21st century. 2018 , 32, 327-335		13
171	Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. 2018 , 15, 461-478		206
170	Noninvasive Evaluation of Fibrosis and Steatosis in Nonalcoholic Fatty Liver Disease by Elastographic Methods. 2018 ,		2
169	Recent advances in understanding and managing non-alcoholic fatty liver disease. 2018 , 7,		32
168	Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study. 2018 , 48, 1099-1107		16
167	Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. 2018 , 8, e021787		58
166	Non-alcoholic fatty liver disease. 2018 , 18, 245-250		64
165	Nonalcoholic Fatty Liver Disease. 2018 , 167-187		0

164	NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. 2018 , 113, 1649-1659		230
163	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. 2019 , 34, 241-248		22
162	Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients. 2019 , 34, 207-214		17
161	Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). <i>Cells</i> , 2019 , 8,	7.9	64
160	Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. 2019 , 13, 849-866		24
159	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. 2019 , 153, 169-177		7
158	The effect of total anthocyanin-base standardized (Cornus mas L.) fruit extract on liver function, tumor necrosis factor β malondealdehyde, and adiponectin in patients with non-alcoholic fatty liver: a study protocol for a double-blind randomized clinical trial. 2019 , 18, 39		8
157	Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. 2019 , 7, 1113-1123		33
156	Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. 2019 , 19, 187-198		10
155	Non-alcoholic fatty liver disease in Asia: How is it different from the West?. 2019 , 34, 1267-1268		4
154	Dairy Foods and Dairy Fats: New Perspectives on Pathways Implicated in Cardiometabolic Health. 2020 , 11, 266-279		10
153	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. 2019 , 153, 169-177		
152	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019 , 68, 2057-2064	19.2	65
151	Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. 2019 , 49, 1136-1146		11
150	Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. 2019 , 79, 903-927		22
149	Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD). 2019 , 18, 445-449		13
148	Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. 2019 , 156, 1264-1281.e4		447
147	MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis. 2019 , 39, 1315-1324		15

146	Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. 2019 , 39, 941-949		31
145	Nonalcoholic Fatty Liver Disease. 2019 , 523-546		
144	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. 2019 , 101, 154005		48
143	Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy. <i>PLoS ONE</i> , 2019 , 14, e0226375	3.7	3
142	Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 633-641	2.2	9
141	Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. 2019 , 18, 1-3		1
140	Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease. 2020 , 55, 100-112		9
139	NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?. 2020 , 10, 88-98		8
138	Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. 2020 , 10, 255-262		18
137	Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. 2020 , 35, 1057-1064		18
136	How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. 2020 , 49, 45-62		2
135	Ultrasound-based liver elastography. 2020 , 109-133		
134	Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107512	3.2	8
133	Comparison of 2D Shear Wave Elastography, Transient Elastography, and MR Elastography for the Diagnosis of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. 2020 , 214, W20-W26		40
132	The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD. 2020 , 54, 107-113		11
131	A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. 2020 , 8,		3
130	Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. 2020 , 112, 154355		8
129	Noninvasive Assessment of Diffuse Liver Diseases Using Vibration-Controlled Transient Elastography (VCTE). 2020 ,		0

128	Quantification of liver function using gadoxetic acid-enhanced MRI. 2020 , 45, 3532-3544		9
127	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. 2020 , 14, 889-919		142
126	Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism. 2020 , 16, 2308-2322		6
125	The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. 2020 , 3, e00127		4
124	Advances in ultrasound elastography for nonalcoholic fatty liver disease. 2020 , 47, 521-533		8
123	Noninvasive diagnostic tools for pediatric NAFLD: where are we now?. 2020 , 14, 1035-1046		3
122	Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. 2020 , 3, e00177		6
121	Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020 , 15, e0238717	3-7	14
120	Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. 2020 , 10,		4
119	Identifying High-Risk NASH Patients: What We Know so Far. 2020 , 12, 125-138		11
118	In Severe Alcoholic Hepatitis, Serum Keratin-18 Fragments Are Diagnostic, Prognostic, and Theragnostic Biomarkers. 2020 , 115, 1857-1868		15
117	Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. 2020 , 111S, 154259		21
116	Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future. 2020 , 40, 331-338		5
115	Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6-3	20
114	Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis. 2020 , 20, 186		8
113	The significance of IL-28B and CK-18 M30 levels in the diagnosis of non-alcoholic steatohepatitis in SD rats. 2020 , 216, 152901		4
112	Are Noninvasive Methods Comparable to Liver Biopsy in Postoperative Patients After Roux-en-Y Gastric Bypass?. 2020 , 30, 2566-2571		2
111	Differenzialdiagnose der Fettlebererkrankung. 2020 , 15, 88-95		

110	Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. 2020 , 50, 682-692		22
109	Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. 2020 , 4, 497-502		12
108	Burden of Disease due to Nonalcoholic Fatty Liver Disease. 2020 , 49, 1-23		22
107	Recruitment and Retention of Patients for Nonalcoholic Steatohepatitis Clinical Trials. 2020 , 49, 123-140		
106	Non-alcoholic Fatty Liver Disease. 2020 , 670-681		1
105	Non-invasive diagnosis of non-alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review. 2020 , 50, 645-655		10
104	Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease. 2020 , 11, e00157		8
103	How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis?. 2021 , 66, 1297-1305		2
102	Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 367-374	6.9	8
101	Non-alcoholic fatty liver disease: A review with clinical and pathological correlation. 2021 , 120, 68-77		7
100	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study.. 2022 , 11, 212-226		0
99	The Role of Transient Elastography in NAFLD. 2021 , 61-74		
98	Nonalcoholic Fatty Liver Disease and Obesity. 2021 , 55, 27-35		0
97	Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. 2021 , 31, 2002-2010		5
96	Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. <i>World Journal of Gastroenterology</i> , 2021 , 27, 609-623	5.6	8
95	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. 2021 , 11,		6
94	Identifying Advanced Fibrosis in NAFLD Using Noninvasive Tests: A Systematic Review of Sequential Algorithms. 2021 ,		
93	Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use?. 2021 , 2021, 6662760		3

92	Caspase-Cleaved Keratin 18 Measurements Identified Ongoing Liver Injury after Bariatric Surgery. 2021 , 10,		3
91	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , 2021 , 11, 5416	4.9	2
90	The role of elastography in non-alcoholic fatty liver disease. 2021 , 67, 164-170		1
89	Transient elastography versus liver biopsy: discordance in evaluations for fibrosis and steatosis from a pathology standpoint. <i>Modern Pathology</i> , 2021 , 34, 1955-1962	9.8	0
88	Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2021 , 11, 14639	4.9	11
87	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 363-401	6.9	21
86	Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, 1451-1458	2.2	0
85	Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. <i>Cureus</i> , 2021 , 13, e17321	1.2	0
84	Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 21, 1065-1078	3.8	1
83	Development and Validation of a Novel Scoring System for Noninvasive Nonalcoholic Steatohepatitis Detection in Bariatric Patients. <i>Obesity Facts</i> , 2021 , 14, 490-500	5.1	0
82	Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2021 ,	4.8	0
81	Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study. <i>Cardiovascular Diabetology</i> , 2021 , 20, 193	8.7	4
80	Screening for nonalcoholic fatty liver disease-when, who and how?. <i>World Journal of Gastroenterology</i> , 2021 , 27, 5803-5821	5.6	1
79	Elastography in Liver-Transplanted Patients. 2021 , 75-89		
78	Ultrasound-based liver elastography in the assessment of fibrosis. <i>Clinical Radiology</i> , 2020 , 75, 822-831	2.9	4
77	Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals. <i>European Journal of Gastroenterology and Hepatology</i> , 2022 , 34, 98-103	2.2	13
76	Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH). <i>Medical Science Monitor</i> , 2018 , 24, 6946-6967	3.2	16
75	Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study. <i>PLoS ONE</i> , 2014 , 9, e111551	3.7	28

74	Performance of real-time elastography for the staging of hepatic fibrosis: a meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e115702	3.7	15
73	Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. <i>PLoS ONE</i> , 2016 , 11, e0147237	3.7	32
72	Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2017 , 5, 261-271	5.2	30
71	Position statement on the diagnosis and management of non-alcoholic fatty liver disease. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2019 , 40, 531-540	1.1	10
70	Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. <i>Current Hypertension Reviews</i> , 2021 , 17, 94-111	2.3	3
69	Application of transient elastography in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 128-141	6.9	34
68	Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. <i>Cancers</i> , 2020 , 12,	6.6	6
67	Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12082-101	5.6	122
66	Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 13493-500	5.6	26
65	Noninvasive imaging assessment of non-alcoholic fatty liver disease: focus on liver scintigraphy. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4432-9	5.6	6
64	Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. <i>World Journal of Gastroenterology</i> , 2018 , 24, 1269-1277	5.6	27
63	Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020 , 26, 5919-5943	5.6	8
62	Transient elastography in clinical detection of liver cirrhosis: A systematic review and meta-analysis. <i>Saudi Journal of Gastroenterology</i> , 2016 , 22, 294-303	3	14
61	Clinical applications, limitations and future role of transient elastography in the management of liver disease. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016 , 7, 91-106	3	38
60	Plasma Levels of K18 Fragments Do Not Correlate with Alcoholic Liver Fibrosis. <i>Gut and Liver</i> , 2019 , 13, 77-82	4.8	3
59	Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2019 , 13, 658-668	4.8	17
58	Development and validation of a neural network for NAFLD diagnosis. <i>Scientific Reports</i> , 2021 , 11, 20240	4.9	2
57	Extrahepatic complication of nonalcoholic fatty liver disease. Is it a causal association?. <i>Interni Medicina Pro Praxi</i> , 2017 , 19, 72-77	0	1

56	Elastography in the Diagnosis of Non-Alcoholic Fatty Liver Disease. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019 , 74, 5-13	0.4	1
55	Introductory Chapter: Nonalcoholic Fatty Liver Disease - What Should We Know?.		
54	Transient Elastography in Chronic Liver Diseases. 2020 , 545-552		
53	The diagnostic conundrum in non-alcoholic fatty liver disease. <i>Exploration of Medicine</i> , 2020 , 1,	1.1	1
52	Biochemical Biomarkers of NAFLD/NASH. 2020 , 89-114		1
51	Detection of NAFLD/NASH in the General Population and in Primary Care Clinics. 2020 , 11-27		
50	Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease. <i>Choonpa Igaku</i> , 2020 , 47, 241-248	0	
49	Non-invasive Diagnostic Approach to NASH: Biological Markers. 2020 , 235-256		
48	Fibrosis Assessment in Patients with NAFLD. 2020 , 123-139		0
47	Diagnostic Algorithm for the Identification of NAFLD in Primary Care. 2020 , 225-234		
46	IV. Evaluation of Liver Fibrosis and Steatosis in Non-alcoholic Fatty Liver Disease. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020 , 109, 34-41	0	
45	Non-invasive Assessment of Non-alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography. 2020 , 115-139		1
44	Extracellular Vesicles in Non-alcoholic Fatty Liver Disease: Key Players in Disease Pathogenesis and Promising Biomarker Tools. 2020 , 157-180		
43	Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
42	Modern Principles of Liver Fibrosis Diagnosis in Patients With Chronic Diffuse Liver Lesions: Literature Review and Clinical Case Description. <i>Lviv Clinical Bulletin</i> , 2020 , 3, 62-72	0.1	
41	Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. <i>Ontario Health Technology Assessment Series</i> , 2015 , 15, 1-45	3.1	12
40	Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Caspian Journal of Internal Medicine</i> , 2016 , 7, 242-252	1	25
39	The Role of Elastography in Non-Alcoholic Fatty Liver Disease. <i>Current Health Sciences Journal</i> , 2020 , 46, 255-269	0.3	

38	ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis.. <i>Surgery for Obesity and Related Diseases</i> , 2021 ,	3	2
37	Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. <i>PLoS ONE</i> , 2021 , 16, e0260313	3.7	2
36	Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.. <i>Cells</i> , 2021 , 10,	7.9	1
35	Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022 , 12, 1815-1829	3.6	
34	Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic Whites in the STELLAR trials.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	1
33	Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.. <i>Metabolic Syndrome and Related Disorders</i> , 2022 ,	2.6	0
32	Non-invasive tests of non-alcoholic fatty liver disease.. <i>Chinese Medical Journal</i> , 2022 , 135,	2.9	1
31	Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches.. <i>Diagnostics</i> , 2022 , 12,	3.8	2
30	The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy.. <i>Medicina (Lithuania)</i> , 2022 , 58,	3.1	
29	Evaluation of Liver Fibrosis Using Shear Wave Elastography: An Overview.		
28	A Machine Learning Based Framework to Identify and Classify Non-alcoholic Fatty Liver Disease in a Large-Scale Population.. <i>Frontiers in Public Health</i> , 2022 , 10, 846118	6	0
27	Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis.. <i>Biomedicines</i> , 2021 , 10,	4.8	3
26	Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approachthe institutional adaptation to existing Clinical Practice Guidelines. 2022 , 2, 12-22		1
25	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).. <i>Endocrine Practice</i> , 2022 , 28, 538-549	3.2	16
24	Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2022 , 108226	3.2	0
23	Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. <i>Obesity Reviews</i> ,	10.6	0
22	NAFLD: Mechanisms, Treatments, and Biomarkers. <i>Biomolecules</i> , 2022 , 12, 824	5.9	3
21	Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis. <i>Gut</i> , gutjnl-2022-327498		

20	Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2022 , 51, 101547	11.3	2
19	Advances in ultrasound elastography for nonalcoholic fatty liver disease. 2022 ,		
18	Fibroscan® and Shear Wave correlated well in hepatic fibrosis evaluation of patients with chronic liver diseases in real life situation. 2022 , 101, e30025		0
17	Benefits of Physical Exercise as Approach to Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Children and Adolescents with Obesity. 2022 , 9, 1174		1
16	Vibration-controlled Transient Elastography in NAFLD: Review Study. 2022 , 12, S41-S45		0
15	The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population. 2022 , 20,		0
14	Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) [April 2022] AWMF Registration No.: 021025. 2022 , 60, e733-e801		0
13	Association between small dense LDL levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease. 2022 , 101, e30527		0
12	Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [April 2022] AWMF-Registernummer: 021025. 2022 , 60, 1346-1421		0
11	Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk. 13,		0
10	Fully connected neural network-based serum surface-enhanced Raman spectroscopy accurately identifies non-alcoholic steatohepatitis.		0
9	A meta-analysis of the diagnostic accuracy of serum type IV collagen 7S concentration for the staging of liver fibrosis in nonalcoholic fatty liver disease.		0
8	Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review. 108-118		3
7	Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease. 13,		0
6	The surveillance of progression and assessment of treatment endpoint for nonalcoholic steatohepatitis.		0
5	Controlled attenuation parameter-insulin resistance (CIR) score to predict non-alcoholic steatohepatitis. 2022 , 12,		0
4	Multiclass Classification of Nonalcoholic Steatohepatitis Mouse Models Using Dielectric Properties as Disease Biomarker. 2022 ,		1
3	Non-Alcoholic Fatty Liver Disease [Changing the Prevalence of Liver Cancer?]. 12-18		0

- 2 Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study. **2023**, 136, 341-350 ○
- 1 Association between Liver Stiffness and Liver-Related Events in HCV-Infected Patients after Successful Treatment with Direct-Acting Antivirals. **2023**, 59, 602 ○